Loading clinical trials...
Loading clinical trials...
A Phase 1 Study to Evaluate the Pharmacokinetics and Safety of Multiple Doses of Cedirogant (ABBV-157) in Subjects With Mild, Moderate and Severe Hepatic Impairment
Conditions
Interventions
Cedirogant
Locations
3
United States
Clinical Pharmacology of Miami /ID# 246573
Miami, Florida, United States
Orlando Clinical Research Ctr /ID# 246052
Orlando, Florida, United States
TX Liver Inst, Americ Res Corp /ID# 246572
San Antonio, Texas, United States
Start Date
July 6, 2022
Primary Completion Date
November 8, 2022
Completion Date
November 8, 2022
Last Updated
December 8, 2022
NCT07324616
NCT04271488
NCT06952634
NCT06841315
NCT06619054
NCT06813781
Lead Sponsor
AbbVie
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions